Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
A collaboration with Bedford, Mass.-based Homology Medicines will expand gene-editing research at Novartis. Homology’s gene-editing technique relies on recently discovered variants of adeno-associated viruses rather than on CRISPR. AAVs induce homologous recombination in a cell’s genome to swap out an old piece of DNA for a new one. The goal is to treat genetic blood and eye diseases. The financial terms are not disclosed, but Novartis previously invested in Homology as part of the firm’s $83.5 million series B funding.
This article has been sent to the following recipient: